Immunotherapy with Immune Checkpoint Inhibitors (ICI), such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, is at the top of interest in cancer research and is now the standard of care for the treatment of several cancers. This evidence concerns the gene CTLA4 and cancer.